Two-micrometer thulium laser resection of the prostate-tangerine technique in benign prostatic hyperplasia patients with previously negative transrectal prostate biopsy

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2017,（2）
• 页码范围: 244-247
• 页数: 4页
• 语种: 英文
• DOI: 10.4103/1008-682X.168790

摘要

The 2?μm thulium laser resection of the prostate?tangerine technique (TmLRP?TT) has been introduced as a minimally invasive treatment for benign prostatic hyperplasia (BPH). This study was undertaken to assess the clinical efifcacy and safety of TmLRP?TT for the treatment of BPH patients with previously negative transrectal prostate biopsy. A prospective analysis of 51 patients with previously negative transrectal prostate biopsy who underwent surgical treatment using TmLRP?TT was performed from December 2011 to December 2013. Preoperative status, surgical details, and perioperative complications were recorded. The follow?up outcome was evaluated with subjective and objective tests at 1 and 6 months. TmLRP?TT was successfully completed in all patients. Mean prostate volume, operative duration, and catheterization time were 93.3 ± 37.9 ml, 69.5 ± 39.5 min, and 6.5 ± 1.3 days, respectively. The mean International Prostate Symptom Score, quality of life score, maximum urinary lfow rate, and post?void residual urine volume changed notably at 6?month follow?up (22.5 ± 6.9 vs 6.1 ± 3.2, 4.8 ± 1.3 vs 1.1 ± 0.9, 7.3 ± 4.5 vs 18.9 ± 7.1 ml s?1, and 148.7 ± 168.7 vs 28.4 ± 17.9 ml). Two (3.9%) patients required blood transfusion perioperatively, while 3 (5.9%) patients experienced transient hematuria postoperatively, and 2 (3.9%) patients received 3 days recatheterization due to clot retention. TmLRP?TT is a safe and effective minimally invasive technique for patients with previously negative transrectal prostate biopsy during the 6?month follow?up. This promising technology may be a feasible surgical method for previously negative transrectal prostate biopsy in the future.